SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
December 15 2022 - 8:30AM
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, high-avidity,
fully-human polyclonal antibodies without the need for human
donors, announced today that SAB Biotherapeutics has been
selected to present at the Biotech Showcase 2023 meeting, an
investor conference that drives biotech innovation and global
collaboration through presentations delivered by innovative biotech
companies, face-to-face networking and one-to-one meetings. The
conference is taking place Jan. 9-11 in San Francisco, in parallel
with the J.P. Morgan 41st Annual Health Care Conference.
Alexandra Kropotova, MD, Executive Vice President, and Chief
Medical Officer of SAB Biotherapeutics, will present at the
Showcase on Tuesday, January 10 at 2:30pm PT. Her presentation will
include an overview of SAB’s novel DiversitAb™ platform, the only
one in the world that produces fully-human, broadly neutralizing,
polyclonal antibodies utilizing transchromosomic cows, and data
from completed clinical trials indicating that these polyclonal
antibody therapies can provide long-lasting efficacy against
multiple types of highly mutating pathogens. During the week of the
conference, potential partners, collaborators, and investors that
are registered and attending the conference may request one-to-one
appointments with the Company through the Biotech Showcase
partnering platform:
https://informaconnect.com/biotech-showcase/
“We are incredibly proud that SAB was among some of the world's
most innovative biotech companies selected to present at the
Biotech Showcase conference,” said Eddie Sullivan, Co-Founder,
President & CEO. “Our team looks forward to sharing details
about SAB’s groundbreaking DiversitAb™ therapeutic platform and its
promising pipeline developments in influenza, Clostridioides
difficile, and other therapeutic areas with high unmet patient
needs with an audience of experienced biotech investors and
respected industry experts.”
- To learn more about partnering
opportunities with SAB Biotherapeutics:
SAB.bio/partnering-opportunities
- For those not registered or
attending Biotech Showcase 2023 but would still like to schedule a
one-to-one meeting during J.P. Morgan week, please contact:
SABIR@westwick.com
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage
biopharmaceutical company focused on the development of powerful
and proprietary immunotherapeutic polyclonal human antibodies to
treat and prevent infectious diseases and immune and autoimmune
disorders. Our development programs include infectious diseases
resulting from outbreaks and pandemics, as well as immunological,
gastroenterological, and respiratory diseases that have significant
mortality and health impacts on immune compromised patients. SAB
has applied advanced genetic engineering and antibody science to
develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™
platform is applicable to a wide range of serious unmet needs in
human diseases. It produces natural, specifically targeted,
high-potency, fully-human polyclonal immunotherapies without the
need for human donors. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio/ and follow SAB
on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, including the development and
efficacy of our influenza program, C. diff. program, Type 1
Diabetes program, and other discovery programs, the likelihood that
a patent will issue from any patent application, the results,
including timing, of the development of SAB-176, SAB-185 and
SAB-195 (including any IND filing or proposed clinical trials),
financial projections and future financial and operating results
(including estimated cost savings and cash runway), the outcome of
and potential future government and other third-party
collaborations or funded programs (including negotiations with the
DoD).
These statements are based on the current expectations of SAB
and are not predictions of actual performance, and are not intended
to serve as, and must not be relied on, by any investor as a
guarantee, prediction, definitive statement, or an assurance, of
fact or probability. These statements are only current predictions
or expectations, and are subject to known and unknown risks,
uncertainties and other factors which may be beyond our control.
Actual events and circumstances are difficult or impossible to
predict, and these risks and uncertainties may cause our or our
industry’s results, performance, or achievements to be materially
different from those anticipated by these forward-looking
statements. A further description of risks and uncertainties can be
found in the sections captioned “Risk Factors” in our most recent
annual report on Form 10-K, subsequent quarterly reports on Form
10-Q, and other filings with or submissions to, the U.S. Securities
and Exchange Commission, which are available
at https://www.sec.gov/. Except as otherwise required by law,
SAB disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events,
or circumstances or otherwise.
CONTACTS
Investor Relations:SAbIR@westwicke.com
Media Relations:SAbPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Jul 2024 to Aug 2024
SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Aug 2023 to Aug 2024